TG Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TGTX | ROIV | B9A.F | VERA | 9969.HK | GMAB | |
|---|---|---|---|---|---|---|
| Market cap | 9.43B | 27.61B | 2.45B | 2.30B | 21.56B | 33.89B |
| P/E (TTM) | 22.4 | — | 250.7 | — | 20.3 | 43.4 |
| Forward P/E | 22.8 | -27.5 | — | -7.5 | 53.2 | 34.9 |
| Price/book | 14.5 | 6.5 | 1.2 | 5.6 | 1.9 | 5.5 |
| Dividend yield | — | — | 0.68% | — | — | — |
| 1-year change | +78.47% | +85.85% | +13.08% | +27.43% | −14.61% | +91.12% |
| Today | +1.45% | +6.08% | −0.29% | +4.10% | +1.33% | −0.72% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TGTX news ›TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
BioSpace TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update CONFERENCE CALL TO BE HELD MONDAY, NOVEMBER 9, 2026, AT 8:30 AM ET NEW YORK--(BUSINESS WI
Turn Therapeutics Inc. (TTRX) - What Are Brokerages Thinking About This Stock?
Check Out Our Latest Analysis on Turn Therapeutics Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. As a group,…
Tiziana Life Sciences (TLSA) Gets a Buy from BTIG
In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Tiziana Life Sciences, with a price target of $7.00. According to TipRanks, Shrader is a 4-star analyst with an average return of 8.1% and a 40.12% success…
Turn Therapeutics (NASDAQ:TTRX) Raised to Hold at Wall Street Zen
Posted by Defense World Staff on Oct 31st, 2026 Turn Therapeutics (NASDAQ:TTRX – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.…
TG Therapeutics: The Business Is More Attractive Than The Valuation
TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance and approaching blockbuster status. Learn why TGTX stock is a hold. - TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance…
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven
Autolus Therapeutics' Q2 2026 saw a 74% sales jump to $45.7M and a gross margin expansion to 55%. I rate AUTL stock as Hold. Click to read my full analysis. - Autolus Therapeutics is rated 'Hold' due to uncertainty around sales…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX) and Insulet (PODD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX) and Insulet (PODD). In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics, with a price…
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, ... - Download the Globe app to my phone…
Tiziana Life Sciences (NASDAQ:TLSA) Upgraded at Wall Street Zen
Posted by Tristan Rich on Oct 27th, 2026 Wall Street Zen upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street…
TG Therapeutics (TGTX) Expected to Post Earnings on Monday
Check Out Our Latest Stock Analysis on TG Therapeutics TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketbeat.com5
- defenseworld.net3
- seekingalpha.com2
- theglobeandmail.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.